- Home
- ATRA
as 07-26-2024 4:00pm EST
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | THOUSAND OAKS |
| Market Cap: | 54.0M | IPO Year: | 2014 |
| Target Price: | $150.70 | AVG Volume (30 days): | 110.9K |
| Analyst Decision: | Hold | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -53.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.98 - $63.38 | Next Earning Date: | 08-06-2024 |
| Revenue: | $34,704,000 | Revenue Growth: | 664.07% |
| Revenue Growth (this year): | 1220.54% | Revenue Growth (next year): | -35.61% |
Stock Insider Trading Activity of Atara Biotherapeutics Inc. (ATRA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Nguyen AnhCo | ATRA | EVP, Chief Sci. & Tech Officer | May 16 '24 | Sell | $0.62 | 42,899 | $26,468.68 | 898,498 | SEC Form 4 |
| Murugan Amar | ATRA | EVP, Chief Legal Officer | May 16 '24 | Sell | $0.62 | 32,401 | $19,991.42 | 695,120 | SEC Form 4 |
| Hyllengren Eric J | ATRA | EVP, CFO | May 16 '24 | Sell | $0.62 | 28,648 | $17,675.82 | 645,671 | SEC Form 4 |
| Touchon Pascal | ATRA | President and CEO | May 16 '24 | Sell | $0.62 | 81,506 | $50,289.20 | 1,829,146 | SEC Form 4 |
| Henrich Jill | ATRA | EVP, Global Head RA & Quality | May 16 '24 | Sell | $0.62 | 25,750 | $15,887.75 | 529,251 | SEC Form 4 |
| Touchon Pascal | ATRA | President and CEO | Mar 4 '24 | Sell | $0.72 | 24,844 | $17,887.68 | 1,910,652 | SEC Form 4 |
| Henrich Jill | ATRA | EVP, Global Head RA & Quality | Mar 4 '24 | Sell | $0.72 | 3,879 | $2,792.88 | 555,001 | SEC Form 4 |
| Nguyen AnhCo | ATRA | EVP, Chief Sci. & Tech Officer | Mar 4 '24 | Sell | $0.72 | 10,746 | $7,737.12 | 941,397 | SEC Form 4 |
| Hyllengren Eric J | ATRA | EVP, CFO | Mar 4 '24 | Sell | $0.72 | 1,462 | $1,054.10 | 679,536 | SEC Form 4 |
| Hyllengren Eric J | ATRA | EVP, CFO | Mar 4 '24 | Sell | $0.72 | 5,217 | $3,756.24 | 674,319 | SEC Form 4 |
| Murugan Amar | ATRA | EVP, Chief Legal Officer | Mar 4 '24 | Sell | $0.72 | 10,044 | $7,231.68 | 727,521 | SEC Form 4 |
| Touchon Pascal | ATRA | President and CEO | Nov 16 '23 | Sell | $0.39 | 20,409 | $7,939.10 | 655,496 | SEC Form 4 |
| Joshi Manher | ATRA | EVP, Chief Medical Officer | Nov 16 '23 | Sell | $0.39 | 12,287 | $4,779.64 | 171,284 | SEC Form 4 |
| Nguyen AnhCo | ATRA | EVP, Chief Sci. & Tech Officer | Nov 16 '23 | Sell | $0.39 | 8,856 | $3,444.98 | 277,143 | SEC Form 4 |
| Murugan Amar | ATRA | EVP, Chief Legal Officer | Nov 16 '23 | Sell | $0.39 | 8,307 | $3,231.42 | 257,084 | SEC Form 4 |
| Henrich Jill | ATRA | EVP, Global Head RA & Quality | Nov 16 '23 | Sell | $0.39 | 3,267 | $1,270.86 | 104,424 | SEC Form 4 |
| Hyllengren Eric J | ATRA | SVP, CFO | Nov 16 '23 | Sell | $0.39 | 11,958 | $4,651.66 | 205,998 | SEC Form 4 |
| HEIDEN WILLIAM K | ATRA | Director | Nov 10 '23 | Buy | $0.25 | 100,000 | $25,330.00 | 209,000 | SEC Form 4 |
| DOBMEIER ERIC | ATRA | Director | Nov 10 '23 | Buy | $0.23 | 446,825 | $101,339.91 | 563,325 | SEC Form 4 |
Latest Atara Biotherapeutics Inc. News
ATRA Breaking Stock News: Dive into ATRA Ticker-Specific Updates for Smart Investing
Pharmaceutical Technology
8 days ago
US FDA grants priority review for Pierre Fabre’s EBV+ PTLD
Pharmaceutical Technology
9 days ago
FDA priority review advances Atara’s tabelecleucel for viral infection
MT Newswires
9 days ago
Atara Biotherapeutics Says Tab-Cel Biologics License Application Gets FDA Priority Review
Business Wire
9 days ago
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
GlobeNewswire
10 days ago
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
Zacks
11 days ago
All You Need to Know About Atara Biotherapeutics (ATRA) Rating Upgrade to Strong Buy
Business Wire
21 days ago
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
23 days ago
Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum
Compare ATRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATRA Atara Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.